Core Insights - Kinder Morgan reported $4.15 billion in revenue for Q3 2025, a year-over-year increase of 12.1% and a surprise of +0.48% over the Zacks Consensus Estimate of $4.13 billion [1] - The company's EPS for the same period was $0.29, which is consistent with the consensus estimate, indicating no EPS surprise [1] Financial Performance Metrics - Realized weighted average oil price was $67.74, slightly above the average estimate of $67.7 [4] - Terminals - Bulk transload tonnage was 12.30 MMTon, below the estimated 12.46 MMTon [4] - Terminals - Liquids leasable capacity was 78.70 MMBBL, exceeding the estimate of 78.58 MMBBL [4] - Realized weighted average NGL price was $31.09, above the estimated $30.9 [4] - Segment EBDA for Products Pipelines was $288 million, slightly below the estimate of $289.29 million [4] - Segment EBDA for Terminals was $274 million, in line with the estimate of $274.2 million [4] - Segment EBDA for Natural Gas Pipelines was $1.39 billion, slightly above the estimate of $1.38 billion [4] - Segment EBDA for CO2 was $135 million, significantly below the estimate of $169.67 million [4] Stock Performance - Kinder Morgan's shares have returned -6% over the past month, while the Zacks S&P 500 composite has increased by +1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Enterprise Products Partners (EPD) reported a revenue of $11.36 billion for the quarter ended June 2025, reflecting a 15.7% decrease year-over-year and a significant miss of 20.03% compared to the Zacks Consensus Estimate of $14.21 billion [1] - The earnings per share (EPS) for the quarter was $0.66, slightly up from $0.64 in the same quarter last year, resulting in a positive surprise of 1.54% against the consensus estimate of $0.65 [1] Financial Performance Metrics - NGL Pipelines & Services reported daily NGL fractionation volumes of 1,667 million barrels, exceeding the average estimate of 1,643.35 million barrels [4] - Fee-based natural gas processing volumes were 7,266 million barrels per day, surpassing the estimated 7,193.4 million barrels [4] - NGL pipeline transportation volumes were 4,562 million barrels per day, slightly below the estimated 4,655.69 million barrels [4] - Natural gas transportation volumes reached 20,405 BBtu/D, exceeding the estimate of 20,257.19 BBtu/D [4] - Gross operating margin for NGL Pipelines & Services was $1.3 billion, lower than the estimated $1.42 billion [4] - Gross operating margin for Crude Oil Pipelines & Services was $403 million, above the estimate of $384.81 million [4] - Gross operating margin for Natural Gas Pipelines & Services was $417 million, significantly higher than the estimated $335.23 million [4] - Gross operating margin for Petrochemical & Refined Products Services was $354 million, below the estimate of $371.52 million [4] Stock Performance - Over the past month, shares of Enterprise Products have returned -2.7%, contrasting with the Zacks S&P 500 composite's +1.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Cencora reported revenue of $80.66 billion for the quarter ended June 2025, reflecting an 8.7% increase year-over-year and surpassing the Zacks Consensus Estimate of $80.33 billion by 0.41% [1] - The company's EPS for the quarter was $4.00, up from $3.34 in the same quarter last year, exceeding the consensus EPS estimate of $3.78 by 5.82% [1] Revenue Breakdown - Total U.S. Healthcare Solutions revenue was $72.88 billion, slightly above the average estimate of $72.81 billion, marking an 8.5% year-over-year increase [4] - Total International Healthcare Solutions revenue reached $7.79 billion, exceeding the average estimate of $7.3 billion, with a year-over-year growth of 10.5% [4] - Intersegment eliminations reported at $-3.47 million, better than the estimated $-3.89 million, showing a significant year-over-year change of 63.6% [4] Stock Performance - Cencora's shares have returned -1.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - Axon Enterprise reported a revenue of $668.54 million for the quarter ended June 2025, reflecting a year-over-year increase of 32.6% and surpassing the Zacks Consensus Estimate by 3.98% [1] - The company's EPS for the quarter was $2.12, significantly higher than the $1.20 reported in the same quarter last year, resulting in an EPS surprise of 37.66% compared to the consensus estimate of $1.54 [1] Financial Performance Metrics - Annual recurring revenue reached $1,183.00 million, exceeding the three-analyst average estimate of $1,148.53 million [4] - Net Sales from Products amounted to $376.36 million, surpassing the average estimate of $364.23 million and showing a year-over-year increase of 27.5% [4] - Net Sales from Services were reported at $292.18 million, exceeding the average estimate of $282.58 million, with a year-over-year growth of 39.9% [4] - Net Sales from Connected Devices - TASER totaled $216.23 million, slightly below the average estimate of $222.91 million [4] - Net Sales from Connected Devices - Platform Solutions reached $67.31 million, significantly above the average estimate of $48.92 million [4] - Net Sales from Software and Services were $292.18 million, exceeding the average estimate of $283.88 million [4] - Overall Net Sales from Connected Devices were $376.36 million, slightly above the average estimate of $366.46 million [4] - Net Sales from Connected Devices - Personal Sensors were reported at $92.82 million, below the average estimate of $94.64 million [4] Stock Performance - Over the past month, Axon shares have returned -6.7%, contrasting with the Zacks S&P 500 composite's +0.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Landstar System (LSTR) reported revenue of $1.21 billion for the quarter ended June 2025, reflecting a year-over-year decline of 1.1% and an EPS of $1.20, down from $1.48 in the same quarter last year [1] - The reported revenue was in line with the Zacks Consensus Estimate, showing a surprise of +0.39%, while the EPS exceeded the consensus estimate by +3.45% [1] Financial Performance Metrics - Revenue per load for Ocean and air cargo carriers was $6,826, below the average estimate of $7,836.56 [4] - Revenue per load for Rail Intermodal was $2,817, compared to the average estimate of $3,011.45 [4] - Total number of loads was 515,770, slightly below the average estimate of 517,459 [4] - Truck Transportation revenue was $1.12 billion, exceeding the average estimate of $1.1 billion, representing a year-over-year increase of +1.1% [4] - Revenue from Ocean and air cargo carriers was $50.79 million, significantly lower than the average estimate of $67.92 million, marking a year-over-year decline of -28.8% [4] - Investment income was reported at $3.73 million, surpassing the average estimate of $3.04 million, with a year-over-year increase of +2.1% [4] Stock Performance - Over the past month, Landstar shares returned +1.6%, while the Zacks S&P 500 composite increased by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - Tenet Healthcare reported revenue of $5.27 billion for the quarter ended June 2025, marking a year-over-year increase of 3.3% and exceeding the Zacks Consensus Estimate by 2.43% [1] - The earnings per share (EPS) for the same period was $4.02, a significant increase from $2.31 a year ago, representing a surprise of 41.55% over the consensus estimate of $2.84 [1] Financial Performance Metrics - Adjusted admissions were reported at 211.52 thousand, below the two-analyst average estimate of 223.82 thousand [4] - Net Operating revenues were $5.27 billion, surpassing the average estimate of $5.13 billion based on four analysts, with a year-over-year change of 3.3% [4] - Net Operating revenues from Ambulatory Care reached $1.27 billion, exceeding the estimated $1.23 billion and reflecting an 11.3% increase compared to the previous year [4] - Hospital Operations and Services generated $4 billion in revenue, compared to the average estimate of $3.92 billion, indicating a 1% year-over-year change [4] - Equity in earnings of unconsolidated affiliates was $61 million, slightly above the average estimate of $60.53 million [4] - Adjusted EBITDA for Hospital Operations and Services was reported at $623 million, exceeding the average estimate of $505.06 million [4] - Adjusted EBITDA for Ambulatory Care was $498 million, slightly above the average estimate of $496.33 million [4] Stock Performance - Tenet's shares have returned 3.3% over the past month, compared to a 5.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Investar (ISTR) reported revenue of $22.27 million for the quarter ended June 2025, marking an 11.6% year-over-year increase and exceeding the Zacks Consensus Estimate of $20.96 million by 6.28% [1] - The company's EPS for the same period was $0.47, up from $0.36 a year ago, representing a surprise of 17.5% compared to the consensus estimate of $0.40 [1] Financial Performance Metrics - Net Interest Margin was reported at 3%, surpassing the average estimate of 2.9% from two analysts [4] - Efficiency Ratio stood at 75%, better than the estimated 76.3% by two analysts [4] - Total Noninterest Income reached $2.63 million, exceeding the estimated $2.12 million [4] - Net Interest Income was reported at $19.64 million, compared to the average estimate of $18.86 million [4] Stock Performance - Investar's shares have returned +19.9% over the past month, outperforming the Zacks S&P 500 composite's +5.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Lowe's reported revenue of $20.93 billion for the quarter ended April 2025, reflecting a 2% decrease year-over-year, with EPS at $2.92 compared to $3.06 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $20.92 billion by 0.03%, while the EPS surpassed the consensus estimate of $2.88 by 1.39% [1] Financial Performance Metrics - Comparable store sales decreased by 1.7% year-over-year, better than the average analyst estimate of a 2.1% decline [4] - The total number of stores remained at 1,750, matching the average estimate from five analysts [4] - Sales per store were reported at $11.96 million, slightly above the average estimate of $11.92 million from two analysts [4] Stock Performance - Over the past month, Lowe's shares returned +5.6%, while the Zacks S&P 500 composite increased by +12.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Sensata reported revenue of $911.26 million for Q1 2025, a year-over-year decline of 9.5%, with EPS of $0.78 compared to $0.89 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $879.52 million by 3.61%, and the EPS also surpassed the consensus estimate of $0.72 by 8.33% [1] Revenue Breakdown - Sensing Solutions generated net revenue of $260.84 million, exceeding the average estimate of $245.61 million, reflecting a year-over-year increase of 1.2% [4] - Performance Sensing reported net revenue of $650.42 million, surpassing the estimated $635.90 million, but showing a year-over-year decline of 8.8% [4] Segment Profit Analysis - Segment profit for Sensing Solutions was $76.07 million, higher than the estimated $69.39 million [4] - Segment profit for Performance Sensing reached $142.88 million, exceeding the average estimate of $137.69 million [4] Stock Performance - Sensata's shares returned +3.9% over the past month, while the Zacks S&P 500 composite increased by +11.3% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Sotera Health Company (SHC) reported revenue of $254.52 million for Q1 2025, marking a year-over-year increase of 2.6% and exceeding the Zacks Consensus Estimate by 3.63% [1] - The earnings per share (EPS) for the same quarter was $0.14, up from $0.13 a year ago, representing a surprise of 16.67% over the consensus estimate of $0.12 [1] Revenue Performance - Sterigenics generated net revenues of $169.68 million, slightly below the average estimate of $169.72 million, reflecting a year-over-year increase of 1.9% [4] - Nelson Labs reported net revenues of $52.28 million, exceeding the average estimate of $51.17 million, but showing a year-over-year decline of 9.4% [4] - Nordion achieved net revenues of $32.56 million, significantly surpassing the average estimate of $22.93 million, with a year-over-year increase of 35.6% [4] Segment Income - Sterigenics reported segment income of $88 million, slightly above the average estimate of $87.92 million [4] - Nelson Labs had segment income of $16.41 million, exceeding the average estimate of $14.20 million [4] - Nordion's segment income was $17.42 million, compared to the average estimate of $10.41 million [4] Stock Performance - Shares of Sotera Health have remained unchanged over the past month, while the Zacks S&P 500 composite experienced a decline of 0.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]